Prognostic significance of proliferative activity and ploidy in node-negative breast cancers
- 1 March 1993
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 4 (3) , 213-219
- https://doi.org/10.1093/oxfordjournals.annonc.a058458
Abstract
Cell kinetics and DNA ploidy have provided relevant information on the natural history of breast cancer. We assessed the prognostic role of proliferative activity and ploidy, alone and in association with tumor size, estrogen (ER) and progesterone (PgR) receptors. In a series of 340 women with resectable node-negative breast cancers given local-regional therapy alone until relapse, proliferative activity was determined as the 3H-thymidine labeling index (3H-dT LI) and flow-cytometric S-phase cell fraction (FCM-S), as quantified by using different modeling systems. DNA ploidy, ER and PgR content were determined on frozen samples by FCM and by the dextran-coated charcoal absorption technique, respectively. FCM-S estimates obtained by the different models were weakly associated with one another and to the corresponding 3H-dT LIs. Four-year relapse-free survival was significantly predicted by 3H-dT LI, ploidy and tumor size but not by FCM-S. Multiple regression analysis showed that 3H-dT LI, ploidy and tumor size retained their prognostic significance and that 3H-dT LI was the most significant indicator of relapse (p – 0.009). The finding that 3H-dT LI and ploidy are weakly related and provide independent prognostic information could allow a more accurate identification of patients at different risk of relapse.Keywords
This publication has 30 references indexed in Scilit:
- DNA ploidy and other results of DNA flow cytometry as prognostic factors in operable breast cancer: 10 year results of a randomised studyEuropean Journal Of Cancer, 1992
- Indicators of Prognosis in Node-Negative Breast CancerNew England Journal of Medicine, 1990
- Cell kinetics as a prognostic indicator in node-negative breast cancerEuropean Journal of Cancer and Clinical Oncology, 1989
- Prediction of Relapse or Survival in Patients with Node-Negative Breast Cancer by DNA Flow CytometryNew England Journal of Medicine, 1989
- Efficacy of Adjuvant Chemotherapy in High-Risk Node-Negative Breast CancerNew England Journal of Medicine, 1989
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989
- A Randomized Clinical Trial Evaluating Sequential Methotrexate and Fluorouracil in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor-Negative TumorsNew England Journal of Medicine, 1989
- Proliferative index of breast carcinoma by thymidine labeling: Prognostic power independent of stage, estrogen and progesterone receptorsBreast Cancer Research and Treatment, 1988
- The DNA labelling index: A prognostic factor in node-negative breast cancerBreast Cancer Research and Treatment, 1987
- Comparing Radical Mastectomy with Quadrantectomy, Axillary Dissection, and Radiotherapy in Patients with Small Cancers of the BreastNew England Journal of Medicine, 1981